| [1] |
Yang QG,He XC,Bai DL.Current status of HIV protease inhibitors[J].Acta Pharm Sin(药学学报),2005,40(5):389-394.
|
| [2] |
Guo DL, Liu GN, Li J, et al. Improved synthesis of raltegravir[J].J China Pharm Univ(中国药科大学学报),2009,40(4):297-301.
|
| [3] |
Molla A,Mo HM,Vasavanonda S,et al.In vitro antiviral interaction of lopinavir with other protease inhibitors[J].Antimicrob Agents Ch,2002,46(7):2249-2253.
|
| [4] |
Liu J,Dong L.The discussion of generic drugs development for Chinese pharmaceutical enterprises[J].Chin Pharm(中国药业),2011,20(16):6-7.
|
| [5] |
Guo ZR,Zhao HY.Challenges and strategies of drug innovation[J].Acta Pharm Sin(药学学报),2013,48(7):1031-1040.
|
| [6] |
Aids Map.Fixed-dose combinations[EB/OL].(2011-03-31)[2014-04-09] .http://www.aidsmap.com/Fixed-dosecombinations/page/1729748/.
|
| [7] |
Walmsley S.Protease inhibitor-based regimens for HIV therapy:safety and efficacy[J].J Acq Imm Def Syn,2007,45(S1):S5-13.
|
| [8] |
Du HZ,Yang Q,Song JY,et al.Research toward approved drugs for anti-HIV/acquired immunodeficiency syndrome and its complications[J].Chin Pharm J(中国药学杂志),2009,44(2):81-87.
|
| [9] |
U.S.Food and Drug Administration.Drug development and drug interactions:table of substrates,inhibitors and inducers[EB/OL].(2006-05-01)[2014-05-20] .http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classInhibit.
|
| [10] |
Sanso G.Double capsule for the administration of active principles in multiple therapies:US,6350486B1[P].2002-02-26[2014-05-25] .
|
| [11] |
Wu JJ,Stranix BR,Ge M,et al.Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors:US,2012/0053139A1[P].2012-05-01[2014-05-25] .
|
下载:
